UNIIBD STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NUMBER
`
`PATENT NUMBER
`
`GROUP ART UNIT
`
`REQUEST ID
`
`15/589,615
`
`10610125
`
`1797
`
`167357
`
`PAIR Correspondence Address/Fee Address Change
`
`The following fields have been changed to Customer Number 51414 on 06/03/2022 via Private PAIR in view of
`the certification copied below that authorized the change.
`
`• Maintenance Fee Address
`
`The address for Customer Number 51414 is:
`51414
`GOODWIN PROCTER LLP
`PATENT ADMINISTRATOR
`100 NORTHERN A VENUE
`BOSTON, MA 02210
`
`I certify, in accordance with 37 CFR 1.4(d)(4) that I am:
`
`An attorney or Agent of Record registered to practice before the Patent and Trademark Office who has been given
`power of attorney in this application
`
`Signature:
`Name:
`Registration Number:
`
`1Ioana Davies/
`Ioana Davies
`75817
`
`Rigel Exhibit 1002
`Page 1 of 1523
`
`

`

`UNIIBD STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NUMBER
`
`PATENT NUMBER
`
`GROUP ART UNIT
`
`REQUEST ID
`
`15/589,615
`
`10610125
`
`1797
`
`167357
`
`PAIR Correspondence Address/Fee Address Change
`
`The following fields have been changed to Customer Number 51414 on 06/03/2022 via Private PAIR in view of
`the certification copied below that authorized the change.
`
`• Correspondence Address
`
`The address for Customer Number 51414 is:
`51414
`GOODWIN PROCTER LLP
`PATENT ADMINISTRATOR
`100 NORTHERN A VENUE
`BOSTON, MA 02210
`
`I certify, in accordance with 37 CFR 1.4(d)(4) that I am:
`
`An attorney or Agent of Record registered to practice before the Patent and Trademark Office who has been given
`power of attorney in this application
`
`Signature:
`Name:
`Registration Number:
`
`1Ioana Davies/
`Ioana Davies
`75817
`
`Rigel Exhibit 1002
`Page 2 of 1523
`
`

`

`UNITED STATES PA TENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONERFORPATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`15/589,615
`
`ISSUE DATE
`
`04/07/2020
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`10610125
`
`AGS-013USC2
`
`7017
`
`148106
`7590
`03/18/2020
`GOODWIN PROCTER LLP/AGIOS
`PATENT ADMINISTRATOR
`100 Northern A venue
`BOSTON, MA 02210
`
`ISSUE NOTIFICATION
`
`The projected patent number and issue date are specified above.
`
`Determination of Patent Term Adjustment under 35 U .S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 101 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office
`of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments
`should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at
`(571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Lenny Dang, Boston, MA;
`Agios Pharmaceuticals, Inc., Cambridge, MA;
`Valeria Fantin, Burlingame, CA;
`Stefan Gross, Brookline, MA;
`Hyun Gyung Jang, Waltham, MA;
`Shengfang Jin, Newton, MA;
`Francesco G. Salituro, Marlborough, MA;
`Jeffrey 0. Saunders, Lincoln, MA;
`Shin-San Michael Su, Boston, MA;
`Katharine Yen, Wellesley, MA;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`Rigel Exhibit 1002
`Page 3 of 1523
`
`

`

`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.
`By mail, send to: Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`By fax, send to:
`
`(571)-273-2885
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)
`
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All
`further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected
`below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.
`Note: A certificate of mailing can only be used for domestic mailings of the
`Fee(s) Transmittal. This certificate cannot be used for any other accompanying
`papers. Each additional paper, such as an assignment or formal drawing, must
`have its own certificate of mailing or transmission.
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`States Postal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being transmitted to
`the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.
`
`148106
`7590
`11/15/2019
`GOODWIN PROCTER LLP
`PATENT ADMINISTRATOR
`100 Northern Avenue
`BOSTON, MA 02210
`
`(Typed or printed name)
`
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`15/589,615
`
`05/08/2017
`
`Lenny Dang
`
`AGS-013USC2
`
`7017
`
`TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREY. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$1000
`
`$0.00
`
`$0.00
`
`$1000
`
`02/18/2020
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`HIXSON, CHRISTOPHER
`
`1797
`
`436-173000
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`0 Change of correspondence address ( or Change of Correspondence
`Address form PTO/SB/122) attached.
`0 "Fee Address" indication (or "Fee Address" Indication form PTO/
`SB/47; Rev 03-09 or more recent) attached. Use of a Customer
`Number is required.
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`
`2. For printing on the patent front page, list
`( 1) The names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`(2) The name of a single firm (having as a member a
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`listed, no name will be printed.
`
`Goodwin Procter LLP
`
`2 ______________ _
`
`3 ______________ _
`
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously
`recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.8l(a). Completion of this form is NOT a substitute for filing an assignment.
`
`(A) NAME OF ASSIGNEE
`
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`Cambridge, MA
`Agios Pharmaceuticals, Inc.
`Please check the appropriate assignee category or categories (will not be printed on the patent) : 0 Individual~ Corporation or other private group entity O Government
`i2?1Issue Fee □Publication Fee (if required)
`□Advance Order - # of Copies _ _ _ _ _ _ _ _ _ _
`4a. Fees submitted:
`4b. Method of Payment: (Please first reapply any previously paid fee shown above)
`0 Enclosed check
`0 Non-electronic payment by credit card (Attach form PTO-2038)
`~ Electronic Payment via EFS-Web
`~ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 07-1700
`
`5. Change in Entity Status (from status indicated above)
`0 Applicant certifying micro entity status. See 37 CFR 1.29
`0 Applicant asserting small entity status. See 37 CFR 1.27
`0 Applicant changing to regular undiscounted fee status.
`
`NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue
`fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`NOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.
`Date _ _ F_e_br_u_a~ry~1_4_, 2_0_2_0 ______ _
`
`Authorized Signature _ _ /_lo_a_n_a_D_a_v_i_e_s_/ ____________ _
`
`Typed or printed name _.,lo.,_a...,_n._.a.._..O..=a._.v._.i,_,e"-s,_ ______________ _
`
`Registration No. -~7~5~8~1~7 __________ _
`
`PTOL-85 Part B (08-18) Approved for use through 01/31/2020
`
`Page 2 of3
`0MB 0651-0033
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`Rigel Exhibit 1002
`Page 4 of 1523
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`15589615
`
`08-May-2017
`
`Title of Invention:
`
`METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED
`DISORDERS
`
`First Named Inventor/Applicant Name:
`
`Lenny Dang
`
`Filer:
`
`Attorney Docket Number:
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111 (a)
`
`loana Davies
`
`AGS-013USC2
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`UTILITY APPL ISSUE FEE
`
`1501
`
`1
`
`1000
`
`1000
`
`Rigel Exhibit 1002
`Page 5 of 1523
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USO($)
`
`1000
`
`Rigel Exhibit 1002
`Page 6 of 1523
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`38580374
`
`15589615
`
`International Application Number:
`
`Confirmation Number:
`
`7017
`
`Title of Invention:
`
`METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED
`DISORDERS
`
`First Named Inventor/Applicant Name:
`
`Lenny Dang
`
`Customer Number:
`
`148106
`
`Filer:
`
`loana Davies
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`AGS-013USC2
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`14-FEB-2020
`
`08-MA Y-2017
`
`10:11:25
`
`Application Type:
`
`Utility under 35 USC 111 (a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`yes
`
`CARD
`
`$1000
`
`RAM confirmation Number
`
`E20202DA11508612
`
`Deposit Account
`
`Authorized User
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Rigel Exhibit 1002
`Page 7 of 1523
`
`

`

`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`File Size(Bytes}/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(if appl.)
`
`127953
`
`1
`
`Issue Fee Payment (PTO-85B)
`
`lssue_Fee_ Transmittal.PDF
`
`no
`
`1
`
`Warnings:
`
`Information:
`
`ce 180e1 3d5fb491 c8998b8ca919abbf969b
`6a8dd
`
`29903
`
`2
`
`Fee Worksheet (5B06)
`
`fee-info.pdf
`
`no
`
`2
`
`1 bcb590d629dc298e356241609623b6ed3
`202616
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes)
`
`157856
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Agglications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`National Stage of an International Agglication under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT /DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Agglication Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 181 O), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/1 OS) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`Rigel Exhibit 1002
`Page 8 of 1523
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Ul\TfED STATES DEPA RTME'IT OF COMMERCE
`United States Patent and Trademark Office
`Adiliess. COMMISSIO'JER FOR PATENTS
`PO Box 1450
`Alexandria, Virgmia 22313-1450
`\VVi\V.USpto.gov
`
`APPLICATION
`NUMBER
`15/589,615
`
`FILING or
`37l(c)DATE
`05/08/2017
`
`GRPART
`UNIT
`1797
`
`FIL FEE REC'D
`2540
`
`148106
`GOODWIN PROCTER LLP/AGIOS
`PATENT ADMINISTRATOR
`100 Northern Avenue
`BOSTON, MA 02210
`
`ATTY.DOCKET.NO
`AGS-013USC2
`
`TOT CLAIMS IND CLAIMS
`18
`1
`CONFIRMATION NO. 7017
`CORRECTED FILING RECEIPT
`
`1111111111111111111111 m~mll!~~ 1~gH~ ~m 11111111111111111111111
`
`Date Mailed: 01/23/2020
`
`Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for
`examination in due course. Applicant will be notified as to the results of the examination. Any correspondence
`concerning the application must include the following identification information: the U.S. APPLICATION NUMBER,
`FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are
`subject to collection.
`
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes
`with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or
`other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt
`with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another
`Filing Receipt incorporating the requested corrections provided that the request is grantable.
`
`lnventor(s)
`
`Lenny Dang, Boston, MA;
`Valeria Fantin, Burlingame, CA;
`Stefan Gross, Brookline, MA;
`Hyun Gyung Jang, Waltham, MA;
`Shengfang Jin, Newton, MA;
`Francesco G. Salituro, Marlborough, MA;
`Jeffrey 0. Saunders, Lincoln, MA;
`Shin-San Michael Su, Boston, MA;
`Katharine Yen, Wellesley, MA;
`
`Applicant( s)
`
`Agios Pharmaceuticals, Inc., Cambridge, MA;
`Assignment For Published Patent Application
`Agios Pharmaceuticals, Inc., Cambridge, MA
`
`Power of Attorney: The patent practitioners associated with Customer Number 148106
`
`Domestic Priority data as claimed by applicant
`This application is a CON of 13/939,519 07/11/2013 ABN
`which is a CON of 13/256,396 11/29/2011 ABN
`which is a 371 of PCT/US10/27253 03/12/2010
`which claims benefit of 61 /266,929 12/04/2009
`and claims benefit of 61/253,820 10/21/2009
`and claims benefit of 61/229,689 07/29/2009
`page 1 of 4
`
`Rigel Exhibit 1002
`Page 9 of 1523
`
`

`

`and claims benefit of 61/227,649 07/22/2009
`and claims benefit of 61/220,543 06/25/2009
`and claims benefit of 61 /180,609 05/22/2009
`and claims benefit of 61 /173,518 04/28/2009
`and claims benefit of 61 /160,664 03/16/2009
`and claims benefit of 61 /160,253 03/13/2009
`
`Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution
`Highway program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
`Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to
`foreign priority. See 37 CFR 1.55 and 1.76.
`
`Permission to Access Application via Priority Document Exchange: Yes
`
`Permission to Access Search Results: Yes
`
`Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as
`appropriate.
`
`If Required, Foreign Filing License Granted: 08/08/2017
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 15/589,615
`Projected Publication Date: Not Applicable
`Non-Publication Request: No
`Early Publication Request: No
`Title
`
`METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
`
`Preliminary Class
`
`436
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`page 2 of 4
`
`Rigel Exhibit 1002
`Page 10 of 1523
`
`

`

`Applicants also are advised that in the case of inventions made in the United States, the Director of the US PTO must
`issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Government hotline at 1-866-999-HAL T (1-866-999-4258).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed
`
`page 3 of 4
`
`Rigel Exhibit 1002
`Page 11 of 1523
`
`

`

`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`Select USA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote and facilitate business investment. SelectUSA provides information assistance to the international investor
`community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call
`+ 1-202-482-6800.
`
`page 4 of 4
`
`Rigel Exhibit 1002
`Page 12 of 1523
`
`

`

`Application Number
`
`Application/Control No.
`
`* 15/589,615 * 15/589,615
`
`Examiner
`
`HIXSON, CHRISTOPHER
`
`Applicant(s)/Patent under
`Reexamination
`
`Dang et al.
`
`Art Unit
`1797
`
`Document Code - DISQ
`
`Internal Document - DO NOT MAIL
`
`TERMINAL
`DISCLAIMER
`
`~ APPROVED
`
`D DISAPPROVED
`
`Date Filed:
`14 November 2019
`
`This patent is subject
`to a Terminal
`Disclaimer
`
`Approved/Disapproved by:
`
`/LAWANA R HIXON/
`
`Technology Center: OPLC
`
`Telephone: (571)272-6074
`
`U.S. Patent and Trademark Office
`TSS-IFW
`
`Terminal Disclaimer
`
`Part of Paper No. 20191119
`
`Rigel Exhibit 1002
`Page 13 of 1523
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Ul\TfED STATES DEPA RTME'IT OF COMMERCE
`United States Patent and Trademark Office
`Adiliess. COMMISSIO'JER FOR PATENTS
`PO Box 1450
`Alexandria, Virgmia 22313-1450
`\VVi\V.USpto.gov
`
`APPLICATION
`NUMBER
`15/589,615
`
`FILING or
`37l(c)DATE
`05/08/2017
`
`GRPART
`UNIT
`1797
`
`FIL FEE REC'D
`2540
`
`148106
`GOODWIN PROCTER LLP
`PATENT ADMINISTRATOR
`100 Northern Avenue
`BOSTON, MA 02210
`
`ATTY.DOCKET.NO
`AGS-013USC2
`
`TOT CLAIMS IND CLAIMS
`18
`1
`CONFIRMATION NO. 7017
`CORRECTED FILING RECEIPT
`
`1111111111111111111111 m~m11!~~ ,~~im,~ 11111111111111111111111
`
`Date Mailed: 11/19/2019
`
`Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for
`examination in due course. Applicant will be notified as to the results of the examination. Any correspondence
`concerning the application must include the following identification information: the U.S. APPLICATION NUMBER,
`FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are
`subject to collection.
`
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes
`with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or
`other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt
`with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another
`Filing Receipt incorporating the requested corrections provided that the request is grantable.
`
`lnventor(s)
`
`Lenny Dang, Boston, MA;
`Valeria Fantin, Burlingame, CA;
`Stefan Gross, Brookline, MA;
`Hyun G. Jang, Waltham, MA;
`Shengfang Jin, Newton, MA;
`Francesco G. Salituro, Marlborough, MA;
`Jeffrey 0. Saunders, Lincoln, MA;
`Shin-San Michael Su, Boston, MA;
`Katharine Yen, Wellesley, MA;
`
`Applicant( s)
`
`Agios Pharmaceuticals, Inc., Cambridge, MA;
`Assignment For Published Patent Application
`Agios Pharmaceuticals, Inc., Cambridge, MA
`
`Power of Attorney: The patent practitioners associated with Customer Number 148106
`
`Domestic Priority data as claimed by applicant
`This application is a CON of 13/939,519 07/11/2013 ABN
`which is a CON of 13/256,396 11/29/2011 ABN
`which is a 371 of PCT/US10/27253 03/12/2010
`which claims benefit of 61 /266,929 12/04/2009
`and claims benefit of 61/253,820 10/21/2009
`and claims benefit of 61/229,689 07/29/2009
`page 1 of 4
`
`Rigel Exhibit 1002
`Page 14 of 1523
`
`

`

`and claims benefit of 61/227,649 07/22/2009
`and claims benefit of 61/220,543 06/25/2009
`and claims benefit of 61 /180,609 05/22/2009
`and claims benefit of 61 /173,518 04/28/2009
`and claims benefit of 61 /160,664 03/16/2009
`and claims benefit of 61 /160,253 03/13/2009
`
`Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution
`Highway program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
`Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to
`foreign priority. See 37 CFR 1.55 and 1.76.
`
`Permission to Access Application via Priority Document Exchange: Yes
`
`Permission to Access Search Results: Yes
`
`Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as
`appropriate.
`
`If Required, Foreign Filing License Granted: 08/08/2017
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 15/589,615
`Projected Publication Date: Not Applicable
`Non-Publication Request: No
`Early Publication Request: No
`Title
`
`METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
`
`Preliminary Class
`
`436
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`page 2 of 4
`
`Rigel Exhibit 1002
`Page 15 of 1523
`
`

`

`Applicants also are advised that in the case of inventions made in the United States, the Director of the US PTO must
`issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Government hotline at 1-866-999-HAL T (1-866-999-4258).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is autom